{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:32:33Z","timestamp":1785439953336,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Northwestern Medicine Enterprise Data Warehouse","award":["NIH grant UL1TR001422"],"award-info":[{"award-number":["NIH grant UL1TR001422"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"DOI":"10.1007\/s10840-025-01990-4","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T12:02:02Z","timestamp":1742126522000},"page":"933-942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Developing a simple clinical risk score for ibrutinib-associated atrial fibrillation"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9655-1186","authenticated-orcid":false,"given":"Tyler A.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Peigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzy P.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,16]]},"reference":[{"issue":"12","key":"1990_CR1","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491\u2013500. https:\/\/doi.org\/10.1016\/j.jacep.2018.06.004.","journal-title":"JACC Clin Electrophysiol"},{"issue":"11","key":"1990_CR2","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918\u201332. https:\/\/doi.org\/10.1001\/jama.2023.1946.","journal-title":"JAMA"},{"issue":"16","key":"1990_CR3","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","volume":"21","author":"RA de Claro","year":"2015","unstructured":"de Claro RA, McGinn KM, Verdun N, et al. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3586\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2225.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1990_CR4","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","volume":"8","author":"T Constantine","year":"2024","unstructured":"Constantine T, Thompson P. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8(9):2300\u20139.","journal-title":"Blood Adv"},{"issue":"5","key":"1990_CR5","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","volume":"5","author":"C Quartermaine","year":"2023","unstructured":"Quartermaine C, Ghazi SM, Yasin A, et al. Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia. JACC CardioOncol. 2023;5(5):570\u201390. https:\/\/doi.org\/10.1016\/j.jaccao.2023.09.002.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"1990_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10840-023-01575-z","volume":"67","author":"C Wei","year":"2024","unstructured":"Wei C, Fazal M, Loh A, et al. Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors. J Interv Card Electrophysiol. 2024;67(1):111\u20138. https:\/\/doi.org\/10.1007\/s10840-023-01575-z.","journal-title":"J Interv Card Electrophysiol"},{"issue":"5","key":"1990_CR7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10840-022-01400-z","volume":"66","author":"M Fazal","year":"2023","unstructured":"Fazal M, Wei C, Chuy KL, et al. Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature. J Interv Card Electrophysiol. 2023;66(5):1165\u201375. https:\/\/doi.org\/10.1007\/s10840-022-01400-z.","journal-title":"J Interv Card Electrophysiol"},{"issue":"1","key":"1990_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaccao.2020.11.016","volume":"3","author":"H Essa","year":"2021","unstructured":"Essa H, Lodhi T, Dobson R, Wright D, Lip GYH. How to manage atrial fibrillation secondary to ibrutinib. JACC CardioOncol. 2021;3(1):140\u20134. https:\/\/doi.org\/10.1016\/j.jaccao.2020.11.016.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"1990_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","volume":"100","author":"WJ Archibald","year":"2021","unstructured":"Archibald WJ, Rabe KG, Kabat BF, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Ann Hematol. 2021;100(1):143\u201355. https:\/\/doi.org\/10.1007\/s00277-020-04094-3.","journal-title":"Ann Hematol"},{"issue":"41","key":"1990_CR10","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"31","key":"1990_CR11","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441\u201352. https:\/\/doi.org\/10.1200\/JCO.21.01210.","journal-title":"J Clin Oncol"},{"issue":"36","key":"1990_CR12","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1093\/eurheartj\/ehad375","volume":"44","author":"L Segan","year":"2023","unstructured":"Segan L, Canovas R, Nanayakkara S, et al. New-onset atrial fibrillation prediction: the HARMS2-AF risk score. Eur Heart J. 2023;44(36):3443\u201352. https:\/\/doi.org\/10.1093\/eurheartj\/ehad375.","journal-title":"Eur Heart J"},{"issue":"2","key":"1990_CR13","doi-asserted-by":"publisher","first-page":"e000102","DOI":"10.1161\/JAHA.112.000102","volume":"2","author":"A Alonso","year":"2013","unstructured":"Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2(2):e000102. https:\/\/doi.org\/10.1161\/JAHA.112.000102.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"1990_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.chest.2018.09.011","volume":"155","author":"YG Li","year":"2019","unstructured":"Li YG, Pastori D, Farcomeni A, et al. A simple clinical risk score (C2HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects. Chest. 2019;155(3):510\u20138. https:\/\/doi.org\/10.1016\/j.chest.2018.09.011.","journal-title":"Chest"},{"issue":"4","key":"1990_CR15","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/hon.2655","volume":"37","author":"A Visentin","year":"2019","unstructured":"Visentin A, Deodato M, Mauro FR, et al. A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematol Oncol. 2019;37(4):508\u201312. https:\/\/doi.org\/10.1002\/hon.2655.","journal-title":"Hematol Oncol"},{"issue":"2","key":"1990_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/10428194.2023.2278433","volume":"65","author":"R Patel","year":"2024","unstructured":"Patel R, Singh A, Meng Z, Baldridge AS, Addison D, Akhter N. The risk vs. benefit calculus of anticoagulation in patients with ibrutinib-related atrial fibrillation. Leuk Lymphoma. 2024;65(2):168\u201374. https:\/\/doi.org\/10.1080\/10428194.2023.2278433.","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"1990_CR17","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","volume":"60","author":"R Lentz","year":"2019","unstructured":"Lentz R, Feinglass J, Ma S, Akhter N. Risk factors for the development of atrial fibrillation on ibrutinib treatment. Leuk Lymphoma. 2019;60(6):1447\u201353. https:\/\/doi.org\/10.1080\/10428194.2018.1533129.","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"1990_CR18","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","volume":"370","author":"T Sanna","year":"2014","unstructured":"Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478\u201386. https:\/\/doi.org\/10.1056\/NEJMoa1313600.","journal-title":"N Engl J Med"},{"issue":"5","key":"1990_CR19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s10840-023-01486-z","volume":"66","author":"G Peigh","year":"2023","unstructured":"Peigh G, Passman RS. Can we predict success when failure is obscured? J Interv Card Electrophysiol. 2023;66(5):1037\u20139. https:\/\/doi.org\/10.1007\/s10840-023-01486-z.","journal-title":"J Interv Card Electrophysiol"},{"issue":"9665","key":"1990_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0140-6736(09)60443-8","volume":"373","author":"RB Schnabel","year":"2009","unstructured":"Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham heart study): a community-based cohort study. Lancet. 2009;373(9665):739\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(09)60443-8.","journal-title":"Lancet"},{"issue":"1","key":"1990_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.amjcard.2010.08.049","volume":"107","author":"AM Chamberlain","year":"2011","unstructured":"Chamberlain AM, Agarwal SK, Folsom AR, et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the atherosclerosis risk in communities [ARIC] study). Am J Cardiol. 2011;107(1):85\u201391. https:\/\/doi.org\/10.1016\/j.amjcard.2010.08.049.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1990_CR22","doi-asserted-by":"publisher","first-page":"e008997","DOI":"10.1161\/CIRCEP.120.008997","volume":"14","author":"S Khurshid","year":"2021","unstructured":"Khurshid S, Kartoun U, Ashburner JM, et al. Performance of atrial fibrillation risk prediction models in over 4 million individuals. Circ Arrhythm Electrophysiol. 2021;14(1):e008997. https:\/\/doi.org\/10.1161\/CIRCEP.120.008997.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"2","key":"1990_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10840-019-00588-x","volume":"58","author":"G Peigh","year":"2020","unstructured":"Peigh G, Kaplan RM, Bavishi A, et al. A novel risk model for very late return of atrial fibrillation beyond 1 year after cryoballoon ablation: the SCALE-CryoAF score. J Interv Card Electrophysiol. 2020;58(2):209\u201317. https:\/\/doi.org\/10.1007\/s10840-019-00588-x.","journal-title":"J Interv Card Electrophysiol"},{"issue":"2","key":"1990_CR24","doi-asserted-by":"publisher","first-page":"e003077","DOI":"10.1161\/JAHA.115.003077","volume":"5","author":"A Alonso","year":"2016","unstructured":"Alonso A, Roetker N, Soliman E, Chen L, Greenland P, Heckbert S. Prediction of atrial fibrillation in a racially diverse cohort: the multi-ethnic study of atherosclerosis (MESA). J Am Heart Assoc. 2016;5(2):e003077.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1990_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.amjcard.2011.03.004","volume":"108","author":"RR Huxley","year":"2011","unstructured":"Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108(1):56\u201362. https:\/\/doi.org\/10.1016\/j.amjcard.2011.03.004.","journal-title":"Am J Cardiol"},{"issue":"5","key":"1990_CR26","doi-asserted-by":"publisher","first-page":"e001211","DOI":"10.1161\/JAHA.114.001211","volume":"3","author":"A Alonso","year":"2014","unstructured":"Alonso A, Yin X, Roetker NS, et al. Blood lipids and the incidence of atrial fibrillation: the multi-ethnic study of atherosclerosis and the Framingham heart study. J Am Heart Assoc. 2014;3(5):e001211. https:\/\/doi.org\/10.1161\/JAHA.114.001211.","journal-title":"J Am Heart Assoc."},{"issue":"10","key":"1990_CR27","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown JR, Moslehi J, O\u2019Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796\u2013805. https:\/\/doi.org\/10.3324\/haematol.2017.171041.","journal-title":"Haematologica"},{"issue":"1","key":"1990_CR28","doi-asserted-by":"publisher","first-page":"e001049","DOI":"10.1136\/openhrt-2019-001049","volume":"6","author":"F Baptiste","year":"2019","unstructured":"Baptiste F, Cautela J, Ancedy Y, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6(1):e001049. https:\/\/doi.org\/10.1136\/openhrt-2019-001049.","journal-title":"Open Heart"},{"issue":"20","key":"1990_CR29","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","volume":"1","author":"TE Wiczer","year":"2017","unstructured":"Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739\u201348. https:\/\/doi.org\/10.1182\/bloodadvances.2017009720.","journal-title":"Blood Adv"},{"issue":"3","key":"1990_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/hon.3126","volume":"41","author":"V Mattiello","year":"2023","unstructured":"Mattiello V, Barone A, Giannarelli D, et al. Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study. Hematol Oncol. 2023;41(3):363\u201370. https:\/\/doi.org\/10.1002\/hon.3126.","journal-title":"Hematol Oncol"},{"key":"1990_CR31","doi-asserted-by":"publisher","unstructured":"Inciardi RM, Wang W, Alonso A, et al. Cardiac mechanics and the risk of atrial fibrillation in a community-based cohort of older adults. Eur Heart J Cardiovasc Imaging. Jul 03 2024;https:\/\/doi.org\/10.1093\/ehjci\/jeae162","DOI":"10.1093\/ehjci\/jeae162"},{"issue":"1","key":"1990_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/echo.14946","volume":"38","author":"A Singh","year":"2021","unstructured":"Singh A, El Hangouche N, McGee K, et al. Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib. Echocardiography. 2021;38(1):81\u20138. https:\/\/doi.org\/10.1111\/echo.14946.","journal-title":"Echocardiography"},{"issue":"1","key":"1990_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15384047.2017.1394554","volume":"19","author":"AR Mato","year":"2018","unstructured":"Mato AR, Clasen S, Pickens P, et al. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer Biol Ther. 2018;19(1):1\u20132. https:\/\/doi.org\/10.1080\/15384047.2017.1394554.","journal-title":"Cancer Biol Ther"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-025-01990-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-025-01990-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-025-01990-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:42:24Z","timestamp":1757133744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-025-01990-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,16]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["1990"],"URL":"https:\/\/doi.org\/10.1007\/s10840-025-01990-4","relation":{},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,16]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}